A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Stopped early · Phase 1/Phase 2
Conditions studied: Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
In brief
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (IV). Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.
Key facts
- Study ID
- NCT04082936
- Run by
- IGM Biosciences, Inc.
- People needed
- 97
- Starts
- 2019-09-30
- Expected to finish
- 2024-02-22
- Last updated by the study team
- 2024-07-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States
- NYU — New York, New York, United States
- MSKCC — New York, New York, United States
- Tennessee Oncology — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Fred Hutch — Seattle, Washington, United States
- Monash Health — Clayton, Victoria, Australia
- St. Vincent's Hospital Melbourne — Fitzroy, Victoria, Australia
- Linear Clinical Resaerch — Nedlands, Western Australia, Australia
- Fakultní nemocnice Královské Vinohrady — Prague, Czechia
- CHU de Poitiers — Poitiers, France
- Gustave Roussy — Villejuif, France
- ASST Papa Giovanni XXIII — Bergamo, BG, Italy
- Fondazione Policlinico Universitario Agostino Gemelli — Roma, RM, Italy
- Azienda Ospedaliero Universitaria di Bologna-Ematologia Bologna — Bologna, Italy
- Seoul National University Hospital — Seoul, South Korea
- Samsung Medical Center — Seoul, South Korea
- Hospital Santa Creu i Sant Pau — Barcelona, Spain
- Hospital Del Mar — Barcelona, Spain
- Hospital de la Santa Creu i Sant Pau — Barcelona, Spain
- Institut Catala d'Oncologia — Barcelona, Spain
- START-Madrid: Fundacion Jimenez Diaz — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.